Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients

Breast

Volumn 18, Issue 2, 2009, Pages 135-141

  Wiesner, Folkward G ^a,b   Magener, Achim ^b   Fasching, Peter A ^b   Wesse, Julia ^b   Bani, Mayada R ^b   Rauh, Claudia ^b   Jud, Sebastian ^b   Schrauder, Michael ^b   Loehberg, Christian R ^b   Beckmann, Matthias W ^b   Hartmann, Arndt ^b   Lux, Michael P ^b  

^a Practice for Gynecology   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Breast cancer; Disease free survival; Ki 67; Overall survival; Prognosis prediction

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; KI 67 ANTIGEN; MOLECULAR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CLINICAL PRACTICE; CONTROLLED STUDY; DATA BASE; DISEASE FREE SURVIVAL; HAZARD RATIO; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR INTERACTION; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICAL SIGNIFICANCE;

EID: 64649087149     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2009.02.009     Document Type: Article

References (37)

1. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thurlimann B., and Senn H.J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 (2005) 1569-1583
2. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thurlimann B., and Senn H.J. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18 (2007) 1133-1144
3. Fasching P.A., Lux M.P., Beckmann K., Strick R., and Beckmann M.W. Prognose-und Prädiktivfaktoren - Entscheidungshilfen bei der Therapiewahl für Patientinnen mit Mammakarzinom. Gynäkologe 38 (2005) 388-397
4. Bloom H.J., and Richardson W.W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11 (1957) 359-377
5. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
6. Elston E.W., and Ellis I.O. Method for grading breast cancer. J Clin Pathol 46 (1993) 189-190
7. Meyer J.S., Alvarez C., Milikowski C., Olson N., Russo I., Russo J., et al. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Mod Pathol 18 (2005) 1067-1078
8. Boiesen P., Bendahl P.O., Anagnostaki L., Domanski H., Holm E., Idvall I., et al. Histologic grading in breast cancer-reproducibility between seven pathologic departments. South Sweden breast cancer group. Acta Oncol 39 (2000) 41-45
9. Gerdes J., Schwab U., Lemke H., and Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31 (1983) 13-20
10. Kill I.R. Localisation of the Ki-67 antigen within the nucleolus. Evidence for a fibrillarin-deficient region of the dense fibrillar component. J Cell Sci 109 6 (1996) 1253-1263
11. Starborg M., Gell K., Brundell E., and Hoog C. The murine Ki-67 cell proliferation antigen accumulates in the nucleolar and heterochromatic regions of interphase cells and at the periphery of the mitotic chromosomes in a process essential for cell cycle progression. J Cell Sci 109 1 (1996) 143-153
12. Urruticoechea A., Smith I.E., and Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23 (2005) 7212-7220
13. de Azambuja E., Cardoso F., de Castro Jr. G., Colozza M., Mano M.S., Durbecq V., et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96 (2007) 1504-1513
14. Viale G., Regan M.M., Mastropasqua M.G., Maffini F., Maiorano E., Colleoni M., et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100 (2008) 207-212
15. Liu S., Edgerton S.M., Moore II D.H., and Thor A.D. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 7 (2001) 1716-1723
16. Moriki T., Takahashi T., Kataoka H., Hiroi M., Yamane T., and Hara H. Proliferation marker MIB-1 correlates well with proliferative activity evaluated by BrdU in breast cancer: an immunohistochemical study including correlation with PCNA, p53, c-erbB-2 and estrogen receptor status. Pathol Int 46 (1996) 953-961
17. Pierga J.Y., Leroyer A., Viehl P., Mosseri V., Chevillard S., and Magdelenat H. Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat 37 (1996) 57-64
18. Pietilainen T., Lipponen P., Aaltomaa S., Eskelinen M., Kosma V.M., and Syrjanen K. The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. J Cancer Res Clin Oncol 122 (1996) 687-692
19. Pinder S.E., Wencyk P., Sibbering D.M., Bell J.A., Elston C.W., Nicholson R., et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 71 (1995) 146-149
20. Rudas M., Gnant M.F., Mittlbock M., Neumayer R., Kummer A., Jakesz R., et al. Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis. Breast Cancer Res Treat 32 (1994) 165-175
21. Sahin A.A., Ro J., Ro J.Y., Blick M.B., el-Naggar A.K., Ordonez N.G., et al. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer 68 (1991) 549-557
22. Sasaki K., Matsumura K., Murakami T., and Tsuji T. Measurement of bromodeoxyuridine labeling index, Ki-67 score and Ag-NOR count in breast carcinomas. Comparison with DNA ploidy. Oncology 49 (1992) 147-153
23. Spyratos F., Ferrero-Pous M., Trassard M., Hacene K., Phillips E., Tubiana-Hulin M., et al. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 94 (2002) 2151-2159
24. Trihia H., Murray S., Price K., Gelber R.D., Golouh R., Goldhirsch A., et al. Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors - a surrogate marker?. Cancer 97 (2003) 1321-1331
25. Weikel W., Beck T., Mitze M., and Knapstein P.G. Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat 18 (1991) 149-154
26. Wintzer H.O., Zipfel I., Schulte-Monting J., Hellerich U., and von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67 (1991) 421-428
27. Brown R.W., Allred C.D., Clark G.M., Osborne C.K., and Hilsenbeck S.G. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2 (1996) 585-592
28. Bottini A., Berruti A., Bersiga A., Brizzi M.P., Bruzzi P., Aguggini S., et al. Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer 85 (2001) 1106-1112
29. Rudolph P., Olsson H., Bonatz G., Ratjen V., Bolte H., Baldetorp B., et al. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol 187 (1999) 207-216
30. Nicholson R.I., McClelland R.A., Finlay P., Eaton C.L., Gullick W.J., Dixon A.R., et al. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 29A (1993) 1018-1023
31. Chhieng D.C., Rodriguez-Burford C., Meleth S., Grizzle W.E., and Ferguson S.M. Assessment of biomarker expression in predicting pathologic response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Breast J 13 (2007) 534-535
32. Keam B., Im S.A., Kim H.J., Oh D.Y., Kim J.H., Lee S.H., et al. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 7 (2007) 203
33. Dowsett M., Smith I.E., Ebbs S.R., Dixon J.M., Skene A., A'Hern R., et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99 (2007) 167-170
34. Blamey R.W., and Cataliotti L. EUSOMA accreditation of breast units. Eur J Cancer 42 (2006) 1331-1337
35. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (2007) 118-145
36. Fonatsch C., Duchrow M., Rieder H., Schluter C., and Gerdes J. Assignment of the human Ki-67 gene (MK167) to 10q25-qter. Genomics 11 (1991) 476-477
37. Heidebrecht H.J., Buck F., Haas K., Wacker H.H., and Parwaresch R. Monoclonal antibodies Ki-S3 and Ki-S5 yield new data on the 'Ki-67' proteins. Cell Prolif 29 (1996) 413-425